Please login to the form below

Not currently logged in

Merck & Co takes Alzheimer's prospect into phase II/III trials

Developed to interrupt formation of amyloid plaques

Merck & Co has started phase II/III trials of Alzheimer's disease therapy candidate MK-8931, the first compound in its class to reach this stage of development.

MK-8931 is leading the field among beta-amyloid precursor protein site-cleaving enzyme (BACE) inhibitors, a new class of orally-available drugs that have been plagued by developmental difficulties, with many early candidates failing to enter or be retained in the central nervous system.

BACE cuts amyloid precursor protein (APP), interrupting the formation of beta amyloid and preventing the formation of the amyloid plaques that are found in patients with the disease.

The hope is that interrupting the plaque formation process early on in the course of the disease could have a greater therapeutic effect than agents such as Pfizer & Johnson & Johnson's bapineuzumab, which was designed to dissolve already-formed plaques and failed in phase III testing.

Merck has started a 78-week trial of MK-8931 in 200 patients with mild-to-moderate Alzheimer's disease called EPOCH which will initially evaluate the safety of MK-8931 in a cohort of 200 patients prior to a larger phase III study.

Earlier this year, Merck presented findings of a multidose phase I study which showed that MK-8931 reduced cerebral spinal fluid (CSF) beta-amyloid by more than 90 per cent in healthy volunteers. Adverse events were generally mild to moderate and included headache, nasal congestion, dizziness, and back pain.

Along with Merck, other companies developing BACE inhibitors include Lilly, Roche and Eisai, although these are all in early-stage testing.

Other emerging classes include gamma secretase inhibitors, despite the failure of lead candidate, Lilly's semagacestat, after late-stage trials revealed serious side effects.

Bristol-Myers Squibb has also encountered problems with gamma secretase inhibitors, terminating the development of avagacestat

4th December 2012

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

We're award-winning joint working specialists. We help our clients to transform healthcare through effective collaboration, and deliver work to feel...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....